Orexo宣布基于粉末的鼻腔疫苗使用 AmorphOX技术配方取得积极数据-动脉网

Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology

CISION 等信源发布 2025-04-10 14:24



可切换为仅中文







The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.

该研究与拥有超过 30 年医学、分子和微生物领域研究经验的平台和疫苗开发商 Abera Bioscience 合作进行。

Both formulations tested induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA).

两种配方在血清中（IgG）以及在鼻腔和肺部局部（IgA）均诱导了强烈的系统性抗体反应。

The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology, AmorphOX®.

该合作符合Orexo扩大其基于粉末的药物递送技术AmorphOX®使用的战略。

UPPSALA,

乌普萨拉，

Sweden

瑞典

，

April 10, 2025

2025年4月10日

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:

ORXOY

奥尔索伊

), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology.

），今天宣布了使用AmorphOX技术配方的粉末鼻腔疫苗候选物的体内概念验证数据积极。

The data was generated under the collaboration between Orexo and Abera Biosciences ('Abera') entered in

该数据是在Orexo与Abera Biosciences（“Abera”）合作下生成的

December 2024

2024年12月

. The aim of the collaboration is to develop mucosal vaccines by combining Orexo's powder-based drug delivery technology AmorphOX with Abera's innovative and patented vaccine platform BERA™.

合作的目的是通过将Orexo基于粉末的药物递送技术AmorphOX与Abera创新且获得专利的疫苗平台BERA™相结合，开发黏膜疫苗。

The proof-of-concept study was conducted in rats where Abera's influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA).

该概念验证研究在大鼠中进行，Abera的流感疫苗候选物通过鼻腔给药，要么配制成液体鼻腔溶液，要么使用Orexo的AmorphOX技术制成鼻腔粉末。两种制剂均在血清中（IgG）诱导了强烈的系统性抗体反应，并在鼻腔和肺部（IgA）局部产生了反应。

No difference in immune response was seen between the liquid nasal solution and the intranasal powder..

鼻腔液体溶液和鼻腔粉末在免疫反应方面没有差异。

An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements..

鼻腔流感疫苗有潜力轻松且有效地帮助减少感染传播和预防疾病，这可能在未来的潜在疫情中发挥重要作用。使用AmorphOX技术将疫苗制成粉末形式，有望开发出成本低、热稳定性强且无需冷链要求的疫苗。

Robert Rönn, SVP and Head of R&D, comments:

Robert Rönn，高级副总裁兼研发主管，评论道：

'We are pleased by these results providing us with important proof-of-concept data for a vaccine formulated in our proprietary powder-based drug delivery technology AmorphOX. The potential benefits from formulating vaccines in powder form are significant, as they can reach so many more patients worldwide.

“我们对这些结果感到满意，因为它们为我们使用专有的基于粉末的药物递送技术AmorphOX所配制的疫苗提供了重要的概念验证数据。以粉末形式配制疫苗的潜在好处是巨大的，因为它们可以让全球更多患者受益。

The study results represent an important milestone in our continued efforts to develop new and innovative drugs.'.

研究结果代表了我们持续开发新的创新药物的重要里程碑。

'It is very encouraging to see that our vaccines perform well in both liquid and powder forms. Powder formulations offer significant advantages in future pandemic scenarios, particularly in terms of simplified logistics, thermal stability, and the potential for self-administration during mass vaccination campaigns.

“看到我们的疫苗在液体和粉末形式下都表现良好，这是非常令人鼓舞的。粉末配方在未来的大流行病情况下具有显著的优势，特别是在简化物流、热稳定性以及在大规模疫苗接种活动中自我施用的潜力方面。”

Orexo's AmorphOX technology is an innovative platform that appears to preserve the immunogenic properties of our vaccine,' .

Orexo的AmorphOX技术是一个创新平台，似乎能够保留我们疫苗的免疫原性特性。

says

说

Mats Lundgren

马茨·伦德格伦

, CSO of Abera Bioscience.

Abera Bioscience首席战略官。

For further information contact:

如需更多信息，请联系：

Nikolaj Sørensen, President and CEO

尼古拉·索伦森，总裁兼首席执行官

Lena Wange

莉娜·王

, IR & Communications Director

，投资者关系与传播总监

Robert Rönn, SVP and Head of R&D

罗伯特·勒恩，高级副总裁兼研发主管

Tel: +46 (0)18 780 88 00

电话：+46 (0)18 780 88 00

E-mail:

电子邮件：

ir@orexo.com

投资者关系@奥雷克斯公司.com

About Orexo

关于Orexo

Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs.

Orexo是一家瑞典制药公司，拥有30年经验，基于满足重大医疗需求的专有配方技术开发改良药物。

On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to

在美国市场上，Orexo 为阿片类药物使用障碍患者提供创新的治疗解决方案。针对其他治疗领域的产品则与全球领先的合作伙伴共同开发和商业化。2024 年的总净销售额达到

SEK 590 million

5.9亿瑞典克朗

, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs on OTCQX market (ORXOY) in the US.

，员工人数达到110人。Orexo在纳斯达克斯德哥尔摩主板上市，并在美国OTCQX市场以美国存托凭证（ORXOY）形式交易。

For more information on Orexo, visit

欲了解有关Orexo的更多信息，请访问

www.orexo.com

. Follow Orexo on X, LinkedIn, and YouTube.

请在X、LinkedIn和YouTube上关注Orexo。

About AmorphOX

关于AmorphOX

Orexo's proprietary drug delivery platform, AmorphOX, is a powder made up of particles that

奥雷克斯公司专有的药物递送平台AmorphOX是一种由颗粒组成的粉末，

are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure. .

是由药物、载体材料以及可选的其他成分的独特组合构建而成。这些颗粒呈现为各种成分的无定形复合物，具有出色的化学和物理稳定性，以及快速溶解性。该技术适用于广泛的活性成分，并在多项人类临床研究中得到验证，显示出快速且广泛的药物暴露。

About Abera Bioscience

关于Abera Bioscience

Abera Bioscience AB is a Swedish vaccine and biotechnology company founded in 2012, originating from molecular biology research at Vrije Universiteit Amsterdam and

Abera Bioscience AB 是一家瑞典疫苗和生物技术公司，成立于2012年，起源于阿姆斯特丹自由大学的分子生物学研究。

Stockholm University

斯德哥尔摩大学

. Abera develops innovative vaccines based on proprietary and patented platform technologies. The vaccine candidates can be administered as nasal sprays and are fast and cost-effective to develop and produce. Using its platform technologies, the company has developed several vaccine candidates and is currently focused on two main areas: pneumococcal vaccines and pandemic preparedness.

Abera 开发基于专有和专利平台技术的创新疫苗。这些候选疫苗可以作为鼻喷雾剂使用，并且开发和生产快速且成本低廉。利用其平台技术，该公司已经开发出多种疫苗候选物，目前主要专注于两大领域：肺炎球菌疫苗和大流行病预防。

The company's lead candidate, Ab-01.12, is a nasal vaccine against pneumococci, being prepared for Phase 1 clinical trials..

公司的主要候选药物Ab-01.12是一种针对肺炎链球菌的鼻腔疫苗，正准备进行一期临床试验。

For more information on Orexo,

有关奥雷克斯的更多信息，请访问

www.aberabio.com

。

About BERA™

关于BERA™

Abera's BERA™ vaccine platform is based on bacterial particles known as OMVs (Outer Membrane Vesicles), which are decorated with a large number of disease-specific antigens. Vaccines based on the BERA platform can be administered as nasal sprays and create protection in both mucosal membranes and systemically in the body, aiming to protect against both disease and transmission.

Abera的BERA™疫苗平台基于被称为OMVs（外膜囊泡）的细菌颗粒，这些颗粒装饰有大量疾病特异性抗原。基于BERA平台的疫苗可以作为鼻喷雾剂使用，并在黏膜和全身产生保护作用，旨在预防疾病及其传播。

The platform technology that enables the rapid development of new vaccine candidates as antigens can be replaced in a plug-and-play manner..

该平台技术能够实现新疫苗候选物的快速开发，因为抗原可以以即插即用的方式进行替换。

The information was submitted for publication at

该信息已提交发布于

8.00 am CET

上午8点（中欧时间）

on April 10, 2025.

2025年4月10日。

This information was brought to you by Cision

此信息由Cision提供

http://news.cision.com